Expression profile of microRNA-29b and its action on matrix metalloproteinase 2 (MMP-2) in the cervical carcinogenic process
DOI:
https://doi.org/10.33448/rsd-v10i11.19471Keywords:
Cervical Cancer; microRNA-29b; Biomarker; Matrix metalloproteinase 2.Abstract
Background: Cervical cancer is the fourth most common cancer among women worldwide. In order to make the diagnosis earlier and more accurate, increase the prospect of using microRNA-29b, which targets matrix metalloproteinase-2 (MMP-2), proteolytic enzymes that play a significant role in the degradation of the important extracellular matrix in progression of cervical carcinogenic lesions. Objectives: The aim of this study was to evaluate the levels of expression of microRNA-29b at all histological levels of carcinogenesis and its relationship with MMP-2 in this type of cancer. Methods: RNA was extracted from eighteen paraffin-embedded biopsy samples diagnosed with carcinoma and 19 considerable healthy samples, after which a real-time PCR technician was performed for expression analysis. Results: Our results show underexpression of microRNA-29b and MMP-2. This decrease in expression was statistically significant and differentiated in the histopathological subtypes. In addition, it has been shown that MMP-2 is directly regulated by microRNA-29b. No other studies were found that performed the same analysis on cervical cancers. Conclusion: Our results indicate a potential diagnosis of microRNA-29b and MMP-2 for lesions and cervical cancer, and show a direct association between these molecules.
References
Acunzo, M., Romano, G., Wernicke, D., Croce, C. M. (2015). MicroRNA and cancer - A brief overview. Advances in Biological Regulation, 57, 1-9.
Barut, M., Kale, A., Kuyumcuoğlu, U., Bozkurt, M., Ağaçayal, E., Özekinci, S. (2015). Analysis of sensitivity, specificity, and positive and negative predictive values of smear and colposcopy in diagnosis of premalignant and malignant cervical lesions. Medical Science Monitor, 21, 3860-7.
Basu, P., Mittal, S., Bhadra, Vale D., Chami, K.Y. (2018). Secondary prevention of cervical cancer. Best Practice & Research: Clinical Obstetrics & Gynaecology, 47, 73-85.
Björklund, M. & Koivunen, E. (2005). Gelatinase-mediated migration and invasion of cancer cells. Biochimica et Biophysica Acta – Reviews on Cancer, 1755, 37-69.
Branca, M., Ciotti, M., Giorgi, C., Santini. D., Di Bonito, L., Costa, S. (2006). Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN. Anticancer Research, 26, 1543-56.
Brummer, O., Böhmer, G., Hollwitz, B., Flemming, P., Petry, K. U., Kühnle, H. (2002). MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation - An immunohistochemical study. Gynecology Oncology, 84, 222-7.
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings National Academy of Science of the United States of America, 101, 2999-3004.
Chakraborti, S., Mandal, M. S., Mandal, A., Chakraborti, T. (2003). Regulation of matrix metalloproteinases. An overview. Molecular and Cellular Biochemistry, 253, 269-85.
Chang, C. & Werb, Z. (2016). The many faces of metalloproteases: Cell growth, invasion, angiogenesis and metastasis. Trends in Cell Biology, 11, S37-43.
Chen, L. H., Hsu, W. L., Tseng, Y. J., Liu, D. W., Weng, C. F. (2016). Involvement of DNMT 3B promotes epithelial-mesenchymal transition and gene expression profile of invasive head and neck squamous cell carcinomas cell lines. BMC Cancer, 16, 431.
Chen, Y., Gao, D. Y., Huang, L. (2015). In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. Advanced Drug Delivery Reviwes, 81, 128-41.
Chou, J., Lin, J. H., Brenot, A., Kim, J. W., Provot, S., Werb, Z. (2013). GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nature Cell Biology, 15, 201-13.
Cardeal, L. B. S., Boccardo, E., Termini, L., Rabachini, T., Andreoli, M. A., Loreto, C. (2012). HPV16 oncoproteins induce MMPs/RECK-TIMP-2 imbalance in primary keratinocytes: Possible implications in cervical carcinogenesis. PLoS One, 7, e33585.
Dehn, D., Torkko, K. C., Shroyer, K. R.(2007). Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer, 111, 1-14.
Fang, J. H., Zhou, H. C., Zeng, C., Yang, J., Liu, Y., Huang, X. (2011). MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology, 54, 1729-40.
Fu, Q., Zhang, J., Huang, G., Zhang, Y., Zhao, M., Zhang, Y. (2020). microRNA-29b inhibits cell growth and promotes sensitivity to oxaliplatin in colon cancer by targeting FOLR1. BioFactors, 46, 136-45.
Globocan Observatory World. (2019). Cancer Today - World. International Agency for Research of Cancer.
He, J., Ye, W., Kou, N., Chen, K., Cui, B., Zhang, X. (2020). MicroRNA-29b-3p suppresses oral squamous cell carcinoma cell migration and invasion via IL32/AKT signalling pathway. Journal of Cellular and Molecular Medicine, 24, 841-849.
Hosoya, A., Lee, J. M., Cho, S. W., Kim, J. Y., Shinozaki, N., Shibahara, T. (2008). Morphological evidence of basal keratinocyte migration during the re-epithelialization process. Histochemistry and Cell Biology, 130, 1165-75.
Hwang, S.J. & Shroyer, K.R. (2012). Biomarkers of cervical dysplasia and carcinoma. Journal of Oncology, 2012, 507286.
Ivanovic, R. F., Viana, N. I., Morais, D. R., Silva, I. A., Leite, K. R., Pontes-Junior, J. (2018). miR-29b enhances prostate cancer cell invasion independently of MMP-2 expression. Cancer Cell International, 18, 18.
Körbler, T., Gršković, M., Dominis, M., Antica, M. (2003). A simple method for RNA isolation from formalin-fixed and paraffin-embedded lymphatic tissues. Experimental and Molecular Pathology, 74, 336-40.
Laengsri, V., Kerdpin, U., Plabplueng, C., Treeratanapiboon, L., Nuchnoi, P. (2018). Cervical Cancer Markers: Epigenetics and microRNAs. Lab Medicine, 49, 97-111.
Li, Y., Zhang, Z., Xiao, Z., Lin, Y., Luo, T., Zhou, Q. (2017). Chemotherapy-mediated miR-29b expression inhibits the invasion and angiogenesis of cervical cancer. Oncotarget, 8, 14655-65.
Lianne D’Oleron Lima Vasconcelos. (2015). Análise imuno-histoquímica das metaloproteinases da matriz 2 e 9 nas lesões intraepiteliais e invasivas da cérvice uterina. Dissertação de Mestrado. Universidade Federal de Pernambuco.
Libra, M., Scalisi, A., Vella, N., Clementi, S., Sorio, R., Stivala, F. (2009). Uterine cervical carcinoma: Role of matrix metalloproteinases (review). International Journal of Oncology, 34, 897-903.
Livak, K. J. & Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods, 25, 402-8.
Ma, Z. (2012). Total RNA Extraction from Formalin-Fixed, Paraffin-Embedded (FFPE) Blocks. Bio-Protocol, 2, e161.
Mundy-Bosse, B. L., Scoville, S. D., Chen, L., Mcconnell, K., Mao, H.C, Ahmed, E. H. (2016). MicroRNA-29b mediates altered innate immune development in acute leukemia. Journal of Clinical Investigation, 126, 4404-16.
Ngankeu, A., Ranganathan, P., Havelange, V., Nicolet, D., Volinia, S., Powell, B. J. (2018). Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget, 9, 4354-65.
Piotr, C. & Nicoletta, S. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate. Analytical Biochemistry, 162, 156-9.
Poudyal, D., Cui, X., Le, P. M., Hofseth, A. B., Windust, A., Nagarkatti, M. (2013). A Key Role of microRNA-29b for the Suppression of Colon Cancer Cell Migration by American Ginseng. PLoS One, 8, e75034.
Qiu, F., Sun, R., Deng, N., Guo, T., Cao, Y., Yu, Y. (2015). MiR-29a/b enhances cell migration and invasion in nasopharyngeal carcinoma progression by regulating SPARC and COL3A1 gene expression. PLoS One, 10, e0120969.
Schmittgen, T. D. & Livak, K. J. (2008). Analyzing real-time PCR data by the comparative CT method. Nature Protocols, 3, 1101-8.
Shinden, Y., Iguchi, T., Akiyoshi, S., Ueo, H., Ueda, M., Hirata, H. (2015). miR-29b is an indicator of prognosis in breast cancer patients. Molecular and Clinical Oncology, 3, 919-23
Sur, S., Steele, R., Shi, X., Ray, R. B. (2019). miRNA-29b Inhibits Prostate Tumor Growth and Induces Apoptosis by Increasing Bim Expression. Cells, 8, 1455.
Wang, H., Guan, X., Tu, Y., Zheng, S., Long, J., Li, S. (2015). MicroRNA-29b attenuates non-small cell lung cancer metastasis by targeting matrix metalloproteinase 2 and PTEN. Journal of Experimental & Clinical Cancer Research, 34, 59.
Wang, H., Wang, T. T., Lv, X. P. (2018). Expression and prognostic value of miRNA-29b in peripheral blood for endometrial cancer. Future Oncology, 14, 1365-76.
World Health Organization.(2014). Comprehensive Cervical Cancer Control: a guide to essencial pratice - Second edition.
Yan, B., Guo, Q., Fu, F. J., Wang, Z., Yin, Z., Wei, Y. B. (2015a). The role of miR-29b in cancer: Regulation, function, and signaling. OncoTargets and Therapy, 8, 539-48.
Yan, B., Guo, Q., Nan, X. X., Wang, Z., Yin, Z., Yi, L.(2015b). Micro-ribonucleic acid 29b inhibits cell proliferation and invasion and enhances cell apoptosis and chemotherapy effects of cisplatin via targeting of DNMT3b and AKT3 in prostate cancer. OncoTargets and Therapy, 8, 557-65.
Yan, M., Yao, C. J., Chow, J. M., Chang, C. L., Hwang, P. A., Chuang, S. E. (2015c). Fucoidan elevates MicroRNA-29b to regulate DNMT3B-MTSS1 axis and inhibit EMT in human hepatocellular carcinoma cells. Marine Drugs, 13, 6099-116.
Zhang, K., Zhang, C., Liu, L., Zhou, J. (2014). A key role of microRNA-29b in suppression of osteosarcoma cell proliferation and migration via modulation of VEGF. International Journal of Clinical Experimental Pathology, 7, 5701-8.
Zur Hausen, H. (2002). Papillomaviruses and cancer: From basic studies to clinical application. Nature Reviews Cancer, 2, 342-50.
Zur Hausen H. (1999). Papillomaviruses in human cancers. Proceedings of the Association American Physicians, 111, 581-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Giwellington Silva Albuquerque; Renata Santos de Oliveira; Jônatas André da Silva Santos; Miquéias Pereira Lima do Amaral; Juliana Maria de Souza; Bárbara de Oliveira Silva; Jacinto da Costa Silva Neto; Maria Tereza Cartaxo Muniz
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
